Similarly, high expression of SHMT2 and MTHFD2 was significantly associated with extrathyroidal extension (ETE), lymph node metastasis, stage III or IV, and the presence of the BRAFV600E mutation in the TCGA cohort (Supplementary Tables 4 and 5). The gene discussed is SHMT2; the disease is metastatic malignant neoplasm in the lymph nodes.